Skip to main content
Premium Trial:

Request an Annual Quote

RevoluGen, GE Healthcare Life Sciences Ink DNA Extraction Product Manufacturing Deal

NEW YORK — UK reagent firm RevoluGen said on Monday that it has signed a global manufacturing deal for its Fire Monkey/Fire Flower high molecular weight DNA extraction and purification product with GE Healthcare Life Sciences.

The Fire Monkey/Fire Flower uses spin columns to extract high molecular weight DNA with an average length of 100 kb or more from animal and bacterial cells, followed by the removal of DNA fragments smaller than 10 kb.

Under the terms of the deal, GE Healthcare Life Sciences will non-exclusively manufacture the product for RevoluGen. Additional terms were not disclosed.

"With this manufacturing agreement we will be able to ensure a high-quality supply of our world-leading Fire Monkey/Fire Flower product from a source sufficiently flexible to be able to cope with any global scale up in demand," RevoluGen CEO Pieter Haitsma Mulier said in a statement.

In mid-2019, RevoluGen signed on Merck KGaA as a non-exclusive global distributor of the Fire Monkey/Fire Flower product.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.